12 May 2019 Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
10 May 2019 Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors
09 May 2019 U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
09 May 2019 Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
08 May 2019 Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
08 May 2019 Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints
08 May 2019 Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
08 May 2019 Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
08 May 2019 Connect Biopharma Reports Positive Phase 1 Data and Announces Initiation of Phase 1b Study in Patients with Atopic Dermatitis for Novel IL-4Rα Antibody CBP-201
07 May 2019 Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
06 May 2019 Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
06 May 2019 Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)
04 May 2019 FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
02 May 2019 Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122
02 May 2019 UCB and University of Lille anti-tau immunotherapy research highlighted in prestigious international scientific journal ‘Brain’
01 May 2019 Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
30 Apr 2019 I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma
30 Apr 2019 European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
30 Apr 2019 Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045
29 Apr 2019 Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
29 Apr 2019 FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States
28 Apr 2019 CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
28 Apr 2019 FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
28 Apr 2019 GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
28 Apr 2019 Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up